Ruxotor 10 mg (Ruxolitinib Phosphate)

Ruxotor 10 mg (Ruxolitinib Phosphate) – Targeted JAK Inhibitor for Blood Disorders

Ruxotor 10 mg (Ruxolitinib Phosphate) is an innovative oral therapy developed to manage certain chronic blood cancers and immune-related conditions. Produced by Everest Pharmaceuticals Ltd. under strict international quality standards and supplied by Saif Pharma, this medication is a trusted option for patients worldwide.

As a Janus kinase (JAK) inhibitor, Ruxotor specifically blocks abnormal JAK1 and JAK2 signaling, which plays a crucial role in driving uncontrolled blood cell growth and immune system overactivation. This makes it highly effective in conditions such as myelofibrosis, polycythemia vera (PV), and graft-versus-host disease (GVHD).

Key Highlights of Ruxotor 10 mg

• Targeted Therapy – Selectively inhibits JAK1 and JAK2, reducing abnormal cell growth.

• Clinically Proven – Demonstrated survival and quality-of-life benefits in pivotal trials.

• Symptom Control – Relieves spleen enlargement, fatigue, fever, night sweats, and bone discomfort.

• Versatile Applications – Used in multiple hematological and immune-related conditions.

• Global Supply via Saif Pharma – Ensures accessibility and affordability in diverse regions.

Indications for Use

Ruxotor 10 mg is prescribed for adult patients with:

1. Myelofibrosis (MF)

• Primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF.

• Ruxotor helps reduce splenomegaly and alleviates disease-related constitutional symptoms.

2. Polycythemia Vera (PV)

• Indicated in patients resistant to or intolerant of hydroxyurea.

• Helps regulate hematocrit levels, lower the risk of blood clots, and reduce phlebotomy dependence.

3. Graft-Versus-Host Disease (GVHD)

• Approved for steroid-refractory acute and chronic GVHD.

• Provides meaningful responses in patients who fail first-line corticosteroid treatment.

Mechanism of Action

Ruxolitinib, the active component of Ruxotor, works by inhibiting JAK1 and JAK2 enzymes. These enzymes transmit signals from cytokine receptors to the cell nucleus, driving cell growth and immune activation.

In blood cancers and GVHD, this pathway becomes overactive, leading to:

• Abnormal proliferation of blood cells.

• Chronic inflammation.

• Organ damage.

By blocking this signaling, Ruxotor restores balance, decreases abnormal blood cell counts, and improves immune regulation.

Dosage and Administration

• Myelofibrosis: 15–20 mg twice daily (based on platelet counts).

• Polycythemia Vera: 10 mg twice daily.

• GVHD: Typically 5–10 mg twice daily.

Administration Notes:

• Take with or without food, at the same time each day.

• Swallow tablets whole with water; do not crush or split.

• Dose adjustments may be required in patients with low blood counts or liver/renal impairment.

Always consult a hematologist/oncologist for personalized dosing.

Clinical Benefits and Efficacy

Ruxotor has been evaluated in several landmark studies:

• COMFORT-I and COMFORT-II Trials (Myelofibrosis):
  • Demonstrated significant reduction in spleen volume.

  • Improved overall survival compared to placebo and best available therapy.

• RESPONSE Trial (Polycythemia Vera):
  • Showed superior hematocrit control and reduced need for phlebotomy.

  • Reduced risk of thrombotic events.

• GVHD Trials:
  • High overall response rates in steroid-refractory patients.

  • Meaningful symptom relief and prolonged survival.

Side Effects

While generally well-tolerated, Ruxotor 10 mg may cause:

Common Side Effects:

• Anemia

• Thrombocytopenia

• Neutropenia

• Headache, dizziness

• Weight gain

• Mild infections

Serious Risks (less common):

• Reactivation of tuberculosis or herpes zoster

• Increased cholesterol/triglycerides

• Elevated liver enzymes

• Rare neurological infections (PML)

Close monitoring ensures safe and effective treatment.

Monitoring Parameters

• CBC (Complete Blood Count): Every 2–4 weeks initially, then periodically.

• Liver Function Tests: To detect early hepatotoxicity.

• Lipid Profile: Especially in long-term use.

• Infection Screening: Prior to initiation, especially for TB and hepatitis.

Contraindications

Ruxotor should not be used in:

• Patients with hypersensitivity to Ruxolitinib.

• Severe uncontrolled infections.

• Pregnant or breastfeeding women.

• Individuals with severe liver dysfunction (without specialist supervision).

Drug Interactions

• CYP3A4 Inhibitors (ketoconazole, clarithromycin) – may raise Ruxolitinib levels.

• CYP3A4 Inducers (rifampicin, carbamazepine) – may lower drug effectiveness.

• Blood Thinners (warfarin, aspirin) – risk of bleeding.

• Immunosuppressants – additive infection risk.

Special Populations

• Elderly Patients: Use with caution, may require lower doses.

• Children ≥12 years (GVHD): Approved under strict supervision.

• Pregnancy/Lactation: Not recommended due to potential fetal and infant risk.

Overdose Management

In overdose cases, patients may develop severe anemia or thrombocytopenia. Supportive treatment, transfusions, and close monitoring are recommended.

Storage

• Store below 30°C (86°F).

• Keep away from direct light and moisture.

• Ensure packaging is tightly closed.

• Keep out of reach of children.

Manufacturer – Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd., based in Bangladesh, is a globally recognized manufacturer of generic and specialty medicines. Known for GMP-compliant facilities, Everest focuses on oncology, hematology, and chronic disease management. Their production of Ruxotor 10 mg ensures both affordability and uncompromised quality.

Supplier – Saif Pharma

Saif Pharma is a leading global supplier of oncology and hematology medicines. By partnering with reputable manufacturers like Everest Pharmaceuticals Ltd., Saif Pharma ensures that patients, hospitals, and healthcare providers worldwide have reliable access to life-saving therapies such as Ruxotor 10 mg (Ruxolitinib Phosphate).

With efficient distribution, regulatory expertise, and commitment to affordability, Saif Pharma continues to support cancer care and rare disease management across multiple regions.

Conclusion

Ruxotor 10 mg (Ruxolitinib Phosphate) is a breakthrough oral therapy that has redefined treatment outcomes in myelofibrosis, polycythemia vera, and steroid-refractory GVHD. By targeting the JAK pathway, it provides meaningful symptom relief, improved survival, and enhanced quality of life.

Manufactured by Everest Pharmaceuticals Ltd. and distributed worldwide by Saif Pharma, Ruxotor combines international quality standards with global accessibility. Whether for patients, physicians, or healthcare distributors, Ruxotor represents a trusted and effective treatment solution.

If you are looking for a reliable supplier of Ruxolitinib Phosphate, choose Saif Pharma – your trusted partner in oncology and hematology care.